Articles by Alexander K. Aust

1. Tracking 4 Payload Trends In Drug Delivery Development 1/22/2024

   Amid new research and development in nanocarriers, market attention has shifted toward payloads and enhancing compatibility. This discussion explores the latest trends and includes a research database.

2. 6 PEG Alternatives You Should Be Thinking About 11/22/2023

   PEGylation is a common way to minimize off-target effects and general toxicity, but it also poses life-threatening risks because it prolongs the drug's time in the bloodstream. Scientists are exploring these alternatives to combat the risk.

3. 4 Major Trends In Lipid Nanoparticle Research 9/7/2023

   When biopharmaceutical consultant Alexander Aust noticed a flood of new research on lipid and polymer nanoparticles pouring out of universities, he started collecting it. Soon, his collection grew enough to reveal trends in the research of nanoparticles in oncology, neurology, infectious disease, and, of course, nucleic acids. He provides a quick overview of those trends and the database with links to published research — more than 300 articles published since 2020.

4. An Independent Expert’s Guide To Picking Nanoparticle Manufacturing Equipment 7/26/2023

   Until recently, nanoparticle manufacturers had to change equipment between preclinical, clinical, and commercial phases. Advances in technology offer more flexibility allowing manufacturers to turn up the dial on the same machines — from early development all the way to commercialization.

5. Draft FDA Labeling Guidance Proposes More Clarity For Providers 3/7/2023

   The FDA's draft guidance for prescription and biologic drugs updates a 2010 guidance and comes following the boom of activity in the biologics space. This article breaks down and analyzes the update on labeling for prescription drugs and biologics on an increasingly complex landscape. 

6. 6 Strategies To Protect Your Biologics Supply Chain In 2023 1/25/2023

   Instead of automating everything — which costs a lot and doesn't solve every problem — drug makers should focus on building scalable, need-specific supply chain operations. This article discusses supply chain resilience strategies biotech companies can reasonably control.